JMP Securities downgraded T-cell therapy developer Adicet Bio (NASDAQ:ACET) to market perform and removed its price target of $19, citing uncertainty about the start date for a pivotal study for the ...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc.

On Wednesday, JMP Securities adjusted its share price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), increasing it to $80 from the previous $60, while maintaining a Market Outperform rating. This ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...